Left to right: Olivia Ferro and Chloe Ferro, co-founders of SheMed (Credit: SheMed)
Female-founded HealthTech firm SheMed has reached unicorn status after a $50 million (£37.3m) Series A funding round, taking its valuation to $1bn (£750m).
The UK-based startup offers a weight-management service for women using GLP-1 medication alongside a digital platform which provides medical advice, data insights and support.
The new funding will be used to expand the firm’s UK operations, scaling its medical and technology teams, strengthening clinical infrastructure and enhancing its data-driven capabilities.
Olivia Ferro, co-founder and chief executive at SheMed, told Digital Health News: “Achieving unicorn status validates the scale of the unmet needs for world class GLP-1 care.
“It shows that personalisation is not a luxury but an expectation of a new generation of women who want care that is data-led, clinically precise, and built around their individual health journey.”
The funding will also support new research and patient-experience initiatives designed to improve access to personalised care for women in the UK.
SheMed’s programme integrates medical oversight, wellness tracking and support through an all-in-one digital platform for women.
Ferro added: “For more than a decade, I searched for answers to an undiagnosed health issue.
“As a GLP-1 patient myself, I know how transformative the right diagnosis and treatment can be.
“We built SheMed to give women the personalised support I struggled to find: care that listens, understands and empowers.”
SheMed was founded in April 2024 by sisters Olivia and Chloe Ferro and since then has cared for more than 60,000 members.
In August, SheMed partnered with MedTech firm Tasso to integrate a blood test into its offerings.
Chloe Ferro, co-founder and president of SheMed, said: “The demand for SheMed’s services has been extraordinary.
“Women are seeking care that recognises their individuality, their biology and their experiences.
“It’s why women continue to turn to SheMed for a tailored, more supportive path to healthcare.”
Later this month, SheMed will publish results from the first-ever female-focused GLP-1 clinical study, marking a significant milestone in women’s metabolic-health research.
The findings will provide insights into how GLP-1 medications affect women’s hormonal and metabolic responses, helping refine future treatment pathways.
SheMed is not disclosing investor information for the Series A round.
It is the second UK-based femtech firm to reach a $1bn valuation, following women’s health app Flo Health’s announcement in July 2024 that it had reached unicorn status after raising more than $200m in Series C funding.
Meanwhile, the NHS is dealing with an increase in demand for GLP-1 medication, used to treat diabetes type 2 and obesity, following the National Institute for Care Excellence recommendation of Tirzepatide for adults with a BMI over 35 and at least one weight-related long-term health condition, published in December 2024.
In January 2025, digital health firm Inhealthcare launched a self-referral service to help NHS organisations manage the expected surge in demand for new weight loss medications.
